ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Amgen strikes immunotherapy deal

by Lisa M. Jarvis
August 8, 2016 | APPEARED IN VOLUME 94, ISSUE 32

Amgen will pay Advaxis $40 million up front and buy $25 million in Advaxis stock for rights to the personalized cancer immunotherapy ADXS-NEO. The treatment is created by sequencing a patient’s healthy and cancer cells to identify neoepitopes, or markers on antigens, that are most likely to prompt an immune response. Advaxis then uses an engineered strain of bacteria to deliver neoepitope peptides directly into cells that tell the immune system to recognize and combat tumor cells. The companies expect to start the first clinical trials of ADXS-NEO next year.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment